Physician profile
Devika Gandhi
NPI 1275024853
$6,724.76
in general payments reported to CMS, 2019-2025
12 companies · $1,250 in 2025
The $1,250 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $428 · 2022: $217 · 2023: $696 · 2024: $4,134 · 2025: $1,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,116 · Food and Beverage: $2,894 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,115.54 |
| Food and Beverage | $2,894.02 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,849.14 | 2023-2025 | Axios, Exalt Model D, Apollo Esg Nxt System |
| Ovesco Endoscopy USA, INC. | $853.53 | 2025 | |
| Janssen Biotech, INC. | $408.67 | 2021-2024 | Tremfya, Stelara |
| Genzyme Corporation | $296.48 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $270.52 | 2021-2023 | Xifaxan |
| Janssen Scientific Affairs, LLC | $265.32 | 2021-2023 | Stelara |
| E.R. Squibb & Sons, L.L.C. | $234.94 | 2022-2023 | Zeposia |
| Fujifilm Healthcare Americas Corporation | $160.00 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $144.14 | 2024 | Terlivaz |
| Gilead Sciences, INC. | $99.99 | 2022 | |
| Aimmune Therapeutics, INC. | $93.88 | 2024 | |
| Abbvie INC. | $48.15 | 2023-2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devika Gandhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.